Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1253
Peer-review started: February 6, 2023
First decision: March 15, 2023
Revised: March 16, 2023
Accepted: May 6, 2023
Article in press: May 6, 2023
Published online: July 15, 2023
Processing time: 156 Days and 5.7 Hours
Bones are one of the most common targets for cancer metastasis. However, bone metastasis (BM) is often underdiagnosed because sensitive diagnostic imaging methods are recommended only after the onset of clinical symptoms. Patients with gastric cancer (GC), especially in advanced stages, are often in a hypercoagulable state.
The purpose of this study was to explore the predictive value of blood indicators on the risk of BM due to GC and to improve the diagnostic efficacy of BM due to GC by screening effective risk factors.
The purpose of this study was to explore whether coagulation indicators can be used as independent risk factors for predicting BM due to GC, thus promoting the early diagnosis and treatment of BM.
We conducted a retrospective study and enrolled 454 patients in this study. Receiver operating characteristic (ROC) curves were used to assess diagnostic performance. Univariate and multivariate logistic regression analyses were used to evaluate the relationship between biomarkers and BM.
ROC curve analysis indicated that coagulation markers have similar or better diagnostic efficacy than traditional GC markers. Based on multivariate logistic regression analysis, prothrombin time, activated partial thromboplastin time and fibrin degradation products were independently associated with BM due to GC. Moreover, age, carcinoembryonic antigen, erythrocyte level and globulin were found to be risk factors of BM. Combining these indicators could improve the effectiveness of diagnosing BM.
Coagulation markers (prothrombin time, activated partial thromboplastin time and fibrin degradation products), carcinoembryonic antigen and globulin were independent risk factors for BM due to GC. Patients with these risk factors should be screened early to detect BM due to GC and prevent bone-related events.
Future research will explore the relationship and molecular mechanism between coagulation and tumor metastasis and explore new targets to block the process of tumor metastasis.